Mizuho Reiterates “Hold” Rating for Nektar Therapeutics (NASDAQ:NKTR)

Mizuho reaffirmed their hold rating on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report sent to investors on Thursday, AnalystRatings.com reports. They currently have a $21.00 price target on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on NKTR. BMO Capital Markets dropped their target price on shares of Nektar Therapeutics from $75.00 to $41.00 and set an outperform rating on the stock in a research report on Friday, August 9th. Jefferies Financial Group downgraded shares of Nektar Therapeutics from a buy rating to a hold rating and dropped their target price for the stock from $59.00 to $23.00 in a research report on Friday, August 9th. TheStreet downgraded shares of Nektar Therapeutics from a c rating to a d rating in a research report on Thursday, August 8th. ValuEngine raised shares of Nektar Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, August 1st. Finally, William Blair restated a buy rating on shares of Nektar Therapeutics in a research note on Thursday, September 26th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of Hold and a consensus price target of $34.43.

NASDAQ:NKTR traded up $0.94 during trading hours on Thursday, hitting $20.98. 7,288,538 shares of the company were exchanged, compared to its average volume of 2,382,446. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of 5.55 and a beta of 2.62. Nektar Therapeutics has a 52-week low of $15.64 and a 52-week high of $47.11. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.09 and a quick ratio of 13.97. The company’s 50 day moving average price is $17.90 and its 200-day moving average price is $26.15.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.17. The company had revenue of $29.22 million for the quarter, compared to the consensus estimate of $26.42 million. Nektar Therapeutics had a negative net margin of 354.90% and a negative return on equity of 25.25%. Nektar Therapeutics’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) EPS. On average, equities analysts predict that Nektar Therapeutics will post -2.85 earnings per share for the current year.

In related news, CFO Gil M. Labrucherie sold 25,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $15.83, for a total value of $395,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jillian B. Thomsen sold 1,809 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $18.15, for a total transaction of $32,833.35. Following the completion of the transaction, the senior vice president now owns 92,668 shares of the company’s stock, valued at $1,681,924.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 169,328 shares of company stock valued at $3,587,957. Company insiders own 4.02% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Investment Advisory Services LLC lifted its stake in shares of Nektar Therapeutics by 1,566.7% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 940 shares during the period. Kavar Capital Partners LLC acquired a new position in shares of Nektar Therapeutics in the 2nd quarter valued at $44,000. Gemmer Asset Management LLC lifted its stake in shares of Nektar Therapeutics by 476.8% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,390 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,149 shares during the period. Liberty Wealth Management LLC lifted its stake in shares of Nektar Therapeutics by 1,402.6% in the 3rd quarter. Liberty Wealth Management LLC now owns 2,870 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 2,679 shares during the period. Finally, Coastal Investment Advisors Inc. lifted its stake in shares of Nektar Therapeutics by 334.3% in the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,937 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 1,491 shares during the period. Hedge funds and other institutional investors own 93.37% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Further Reading: Intrinsic Value

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.